Members of the NF-kB/Rel transcription factor family have been shown recently to be required for cellular transformation by oncogenic Ras and by other oncoproteins and to suppress transformation-associated apoptosis. Furthermore, NF-kB has been shown to be activated by several oncoproteins including HER2/Neu, a receptor tyrosine kinase often expressed in human breast cancer. Human breast cancer cell lines, human breast tumors and normal adjacent tissue were analysed by gel mobility shift assay, immunoblotting of nuclear extracts and immunohistochemistry for activation of NF-kB. Furthermore, RNA levels for NF-kB-activated genes were analysed in order to determine if NF-kB is functionally active in human breast cancer. Our data indicate that the p65/RelA subunit of NF-kB is activated (i.e., nuclear) in breast cancer cell lines. However, breast tumors exhibit an absence or low level of nuclear p65/RelA but show activated c-Rel, p50 and p52 as compared to nontumorigenic adjacent tissue. Additionally, the IkB homolog Bcl-3, which functions to stimulate transcription with p50 or p52, was also activated in breast tumors. There was no apparent correlation between estrogen receptor status and levels of nuclear NF-kB complexes. Transcripts of NF-kB-regulated genes were found elevated in breast tumors, as compared to adjacent normal tissue, indicating functional NF-kB activity. These data suggest a potential role for a subset of NF-kB and IkB family proteins, particularly NF-kB/p52 and Bcl-3, in human breast cancer. Additionally, the activation of functional NF-kB in these tumors likely involves a signal transduction pathway distinct from that utilized by cytokines.
Introduction
As with virtually all malignancies, breast cancer is associated with dysregulated expression of growth factors and growth factor receptors as well as kinases associated with growth factor signaling pathways (Dickson and Lippman, 1995; Resnik et al., 1998) . The ultimate downstream eectors of these pathways are transcription factors. Thus, dysregulated transcription is likely to play an important role in cancer since it has been shown that the transcription factors c-jun, ets, c-myc and NF-kB are each required for cellular transformation controlled by oncogenic Ras alleles (Johnson et al., 1996; Langer et al., 1992; Sklar et al., 1991; Finco et al., 1997) . The ultimate gene targets of these transcription factors that contribute to oncogenesis are poorly understood.
NF-kB is a transcription factor that is known to play an important role in controlling immune and in¯ammatory responses (see Ghosh et al., 1998; Verma et al., 1995) . There are presently ®ve members of the mammalian NF-kB/Rel family: NFkB/p50, NF-kB2/p52, c-Rel, RelA/p65 and RelB. The p50 and p52 NF-kB subunits are derived from larger precursor products, p105 and p100 respectively, or from dierential translation of their mRNAs. The classic form of NF-kB, the heterodimer of the p50 and 65 subunits, is normally retained in the cytoplasm through interactions with inhibitor proteins IkBa and IkBb. Inductive stimuli (TNFa, IL-1, bacterial endotoxin, etc.) lead to the phosphorylation and degradation of IkB, allowing NF-kB to enter the nucleus and regulate gene expression (reviewed in Ghosh et al., 1998; Verma et al., 1995) . IkBa is inducibly phosphorylated on serines 32 and 36 following activation of the IkB kinase complex (Ghosh et al., 1998) . Following its degradation, IkBa is transcriptionally upregulated due to NF-kB sites in its promoter which leads to a suppression of p65-and cRel-containing heterodimers. IkBb also interacts with the same heterodimers as IkBa but is degraded with slower kinetics and functions in the persistent activation of NF-kB (Ghosh et al., 1998) . Bcl-3, a noninhibitory member of the IkB family (Ohno et al., 1990; Kerr et al., 1992) that is associated with certain leukemias and lymphomas (McKeithan et al., 1997) , functions to stimulate transcription through interactions with the p50 or p52 NF-kB subunits (Bours et al., 1993; Fujita et al., 1993) and to increase nuclear levels of p50 homodimers (Zhang et al., 1994; Watanabe et al., 1997) . Bcl-3-p50 complexes can be activated following inducible phosphorylation of the p105 precursor by the IkB kinase . Recently, it was shown that Bcl-3 interacts with transcriptional co-activators, including the Tip60 histone acetyltransferase (Dechend et al., 1999) . Gene knockout studies con®rm the important roles of the NF-kB family in immune function and also indicate that the RelA/p65 subunit is required to suppress liver cell apoptosis (reviewed in Ghosh et al., 1998; Verma et al., 1995 ; and see Beg et al., 1995) .
Additionally we, Wang et al. (1996) , and others (Arsura et al., 1996; Beg and Baltimore, 1996; Liu et al., 1996; Van Antwerp et al., 1996; Chu et al., 1997) , have shown that NF-kB suppresses apoptosis initiated by tumor necrosis factor, chemotherapy or radiation.
Evidence for a role of NF-kB in oncogenesis is extensive. The founding member of the NF-kB family, c-Rel, is the cellular homolog of v-Rel, the transforming gene of avian reticuloendotheliosis virus (Gilmore, 1997) . One of the NF-kB genes, NF-kB2/p52 (lyt-10), is found translocated in some lymphoid neoplasms (Chang et al., 1995) as is the IkB family member Bcl-3 (McKeithan et al., 1997; Michaux et al., 1997) . Furthermore, several oncoproteins, including HER2/ Neu, Ras and Bcr-Abl, are known to activate NF-kB and NF-kB is required for transformation induced by Ras and by Bcr-Abl (Galang et al., 1996; Finco et al., 1997; Reuther et al., 1998) . Importantly, NF-kB activation suppresses a transformation-induced apoptosis associated with oncogenic Ras expression (Mayo et al., 1997) and expression of the RelA/p65 subunit is required for growth of Hodgkin's lymphoma (Bargou et al., 1997) . Consistent with this, IkBa is found mutated in certain cases of Hodgkin's disease (Cabannes et al., 1999) . Recently, it was shown that NFkB transcriptionally regulates the gene encoding cyclin D1 and, correspondingly, promotes cell growth (Hinz et al., 1999; Guttridge et al., 1999) .
NF-kB expression has been analysed in human breast cancer cell lines and in breast cancer tissue. Dejardin et al. (1995) found that the 100 kD precursor of the NF-kB2/p52 subunit was overexpressed in a majority of breast cancer samples and in cancer cell lines, suggesting a role for the precursor in retaining classic forms of NF-kB in the cytoplasm. Nakshatri et al. (1997) found that NF-kB RelA/p65 is activated (i.e., nuclear) in the majority of human breast cancer cell lines and that the relative level of NF-kB was inversely correlated with estrogen receptor (ER) expression. Recently, Sonenshein and colleagues (Sovak et al., 1997) found increased levels of NF-kB in human breast cancer samples and that inhibition of NF-kB in a breast cancer cell line led to apoptosis. We have explored the NF-kB subunit composition in human breast tumors and have found that the p50, p52, and cRel subunits are found in the nucleus in virtually all samples of breast cancer. Importantly, the p52 subunit was signi®cantly upregulated in tumor tissue as compared to stromal ®broblasts or adjacent, nontumor breast epithelium. There was no apparent correlation between ER status and NF-kB activation in the tumor samples. Interestingly, the p65 subunit was activated in breast cancer cell lines but was not activated to a signi®cant level in breast cancer. Furthermore, the IkB homolog Bcl-3, which has been shown to function with p50 and p52 subunits to stimulate transcription (Bours et al., 1993; Fujita et al., 1993) and which is associated with leukemia (McKeithan et al., 1997; Michaux et al., 1997) , was also found to exhibit increased nuclear levels in human breast cancer as compared to non-tumor tissue but was not increased in human breast cancer cell lines. Consistent with these observations, transcripts of known NF-kB-regulated genes were found to be signi®cantly elevated in human breast cancer tissue. These data indicate that NF-kB is functionally active in human breast cancer and that a subset of NF-kB complexes, which do not include the p50/p65 heterodimer, is activated in human breast cancer. Furthermore, the results suggest that non-typical mechanisms are involved in activation of functional NF-kB in breast cancer.
Results

NF-kB binding activity is increased in breast cancer cell lines
In many instances the utilization of immortalized or transformed cell lines is widely recognized as an appropriate model to test the function of a particular transcription factor. In order to determine whether NF-kB plays a role in breast cancer, we examined several breast cancer cell lines for the activation of NFkB. Activation of NF-kB is characterized by an increase in nuclear NF-kB, an event that can be monitored through electrophoretic mobility shift assays (EMSAs). We analysed ®ve well characterized breast cancer cell lines: MCF7, T47D, MDA231, SKBR3 and BT474. Nuclear extracts from each of these cell lines were incubated with a radiolabeled oligonucleotide probe containing an NF-kB DNA binding site. Nuclear extracts from SKBR3 cells contain the strongest NF-kB binding complex followed by BT474, MDA231 and MCF7 (Figure 1a) . Nuclear extracts from T47D cells contain very little NF-kB DNA binding activity. Similar data were obtained using dierent nuclear extract preparations (data not shown). To identify which NF-kB components contribute to this binding activity, we performed supershift analysis with NF-kB speci®c antibodies. An antibody speci®c for the p65 subunit of NF-kB, which can recognize p65 homodimers and p50/p65 heterodimers of NF-kB, supershifted complex I and was unable to shift complex II (Figure 1b) . However, both complexes I and II are supershifted when a p50 antibody, which recognizes both p50 homodimers and p50/p65 heterodimers, and when a p52 antibody were used. When an antibody speci®c for c-Rel is added to the binding reaction there appears to be a decrease in DNA binding but no visible supershift complex is formed. The relative lack of c-Rel binding is not due to the oligonucleotide probe favoring binding of p65 over that of c-Rel, since nuclear extracts prepared form WEHI-231 cells, known to contain high levels of c-Rel binding activity, show that the probe is readily bound by c-Rel (data not shown). These data suggest that there is an increase in NF-kB DNA binding complexes in nuclear extracts of breast cancer cell lines. The greatest NF-kB binding activity occurs with complexes containing the p65 subunit of NF-kB, a classic NF-kB component.
A recent study demonstrated that estrogen receptor (ER) negative breast cancer cell lines contain an increase in constitutive NF-kB DNA binding when compared to ER-positive cell lines (Nakshatri et al., 1997) . In our study we ®nd that the ER negative SKBR3 cell line does show the greatest NF-kB binding complexes (Figure 1 ), however NF-kB binding complexes formed in the ER-positive cell line BT474 are only slightly lower. In addition, by Western analysis, the ER positive cell line MCF-7 appears to have the highest expression of both p65 and c-Rel proteins (data not shown). We have also observed by Western analysis that the ER-positive T47D cell line, which has very little NF-kB binding activity, appears to have p65 and p105 of slightly altered mobility (data not shown and see Figure 4b ). The altered protein expression in these cells may contribute to the lack of NF-kB DNA binding observed in EMSA (Figure 1b) , and probably has nothing to do with the ER status in that cell line. The fact that we do not observe a strong correlation with NF-kB and ER activity in these cell lines may be due to the fact that cell lines carried in culture can show great dierences in the amount of NF-kB present over time. In addition, slight changes in culture media and the source of the original cell may also contribute to these dierences.
Primary tumor cells from patients with breast cancer exhibit increased NF-kB binding activity
Although we have analysed NF-kB DNA binding in breast cancer cell lines, we were interested in determining the status of NF-kB activity in cells from primary breast tumors. Seventeen cases of carcinomas of the breast were received from Lineberger Comprehensive Cancer Tissue Procurement ®les. Sixteen were primary breast carcinomas, and one was a local recurrence. Twelve cases were pure ductal, ranging in size from 0.4 ± 9 cm in diameter and ranging from grade 1 ± 3. Of these cases for which steroid receptor data are available, 3/8 were ER positive and 3/6 were PR positive. Two cases were mixed ductal and lobular, ranging in size from 0.4 ± 5 cm and ranging from grade 1 ± 2. Of the cases of this group for which steroid receptor data are available, 2/2 were ER positive and 2/2 were PR positive. Two cases were pure lobular, ranging in size from 1.7 cm to diuse (420 cm) and ranging from nuclear grade 1 ± 2. Of these cases for which steroid receptor data are available, 1/2 were ER positive, and 1/2 were PR positive.
Nuclear extracts from snap frozen tissue sections of primary breast tumors and normal adjacent breast tissue were obtained from nuclei isolated by sucrose pad puri®cation. EMSAs were performed on nuclear extracts and DNA binding activity between tumor (T) and adjacent tissue (A) was analysed. The results show that all tumor samples contain NF-kB speci®c DNA binding activity (Figure 2a) . Although patient 1 appears to have the highest level of NF-kB binding activity, all seven patients show a dramatic increase in NF-kB DNA binding complexes when compared to their nontumorigenic adjacent tissue. Although the absolute levels of NF-kB binding activity vary between tumorigenic patient samples, all have correspondingly higher binding activity than their adjacent tissue ( Figure 2a ). The level of NF-kB binding does not appear to be related to the estrogen receptor status since both ER+ and ER7 samples exhibit high levels of NF-kB binding (Figure 2a) .
To identify which components of NF-kB contribute to this binding activity, supershift analysis was performed with nuclear extracts from patient 7 ( Figure  2b ). Supershift analysis identi®ed p50, p52 and c-Rel as the predominant NF-kB subunits contained in these binding complexes (Figure 2b ). It is noted that these antibodies do not strongly reduce the major DNA/ protein complex, which may be due to an opposing stabilization of the complex by the immune serum or to the inability of the complex to be eciently recognized by the antiserum. It also remains possible that an additional, uncharacterized subunit is part of the major DNA binding activity. Antibodies to RelB did not aect the DNA/protein complex (data not shown). Surprisingly when a p65 speci®c antibody which recognized both p65 homodimers and p50/p65 heterodimers was added to the binding reaction only the very faint upper complex seen is supershifted. This complex appears in only three of the 17 patient samples analysed and thus does not appear to be an important factor in the overall upregulation of NF-kB activity in primary breast tumor cells. The DNA binding activity obtained with tumor nuclear extracts is speci®c as shown by competition with the cold probe (UV21) and with a shorter, commercially available consensus NFkB oligonucleotide (Figure 2c ). The EMSA complexes detected with breast cancer nuclear extracts do not appear to contain NF-kB binding complexes identi®ed as complex I in breast cancer cell lines, since the tumor-derived DNA-protein complexes are faster migrating than the predominant p50/p65 heterodimer complex found in the cell lines (see Figure 2c ). From these results we conclude that the increase in NF-kB DNA binding present in the nuclear extracts from breast tumor cells appears to represent an increase in p50, p52 and c-Rel but not p65. Similar results were obtained in all tumor and adjacent samples tested (data not shown). In order to con®rm the statistical signi®cance of our previous result, EMSAs were performed on additional patient tumor samples. The results from these patients demonstrate that NF-kB DNA activity is elevated in 10/10 breast tumors examined (data not shown). Thus, we have examined tumors from 17 patients and every patient sample exhibited an increase in NF-kB binding activity. Surprisingly, these NF-kB complexes do not involve signi®cant levels of p65, the most commonly analysed NF-kB component. Although a few patients (3/17) showed an increase in p65 binding activity in breast tumors, the level of binding is signi®cantly less than exhibited by the major complex. These data indicate that NF-kB family members other than p65 are upregulated in breast tumors.
Immunohistochemistry indicates an increase in p50/NF-kB1, p52/NF-kB2, and c-Rel proteins in breast tumors
To initially determine if p50, p52 and c-Rel are present at higher levels in breast tumor samples as compared to their normal adjacent tissues, immunohistochemistry was performed using NF-kB speci®c on paran embedded sections of normal and tumorigenic breast tissue from patients 1 and 2. The results shown in Figure 3 are from patient 1 and demonstrate an increase in p52 and c-Rel protein levels in breast tumors when compared to nontumorigenic adjacent tissue. The increased staining for c-Rel appears to be in the in®ltrating ductal regions as well as in the surrounding stromal cells indicating an overall increase in staining in the tumor section. However, the staining for p52 is speci®cally increased in the cancerous ductal regions of the tumor section, with very little staining observed in the stromal cells, suggesting that the increase in p52 protein is seen primarily in the cancer cells. There is also an increase in staining in the tumor samples when compared to adjacent tissue using the p50 speci®c antibody. Staining with an antibody for the p65 subunit of NF-kB indicates that there is some dierence in p65 protein levels between adjacent and tumor tissue. To determine whether the staining seen with the p65 antibody is nuclear, an antibody speci®c for the activated form of p65 (p65-NLS, which recognizes p65 released from IkB) was utilized and no antibody speci®c staining in either the adjacent or tumor sections is detectable (data not shown). Therefore, breast cancer tissues contain increased NF-kB involving the NF-kB subunits p50, p52, and c-Rel. The upregulation of p52 appeared to be more speci®c for tumor cells. Because of the large quantity of cytoplasmic staining for each of the samples and the high background with some of the antibodies, it is dicult to determine whether there is a corresponding increase in nuclear staining, thus we have directly measured nuclear levels of NF-kB subunits. Additionally, the immunohistochemistry does not distinguish between expression of the precursor forms (p100 and p105) and the processed forms (p50 and p52) of these NF-kB sunumits.
NF-kB subunits p50, p52 and c-Rel as well as Bcl-3 are increased in nuclei of breast cancer cells
To correlate the increases in p52, p50 and c-Rel seen in EMSA and in the immunohistochemistry experiments with actual protein levels, Western blot analysis was performed using the nuclear extracts examined in Figure  2 . Nuclear proteins were electrophoresed on an SDS Figure 4a . An increase in nuclear p50, p52, and c-Rel protein levels is observed in each tumor sample when compared to adjacent nontumorigenic tissue. In agreement with our EMSA data, there was little detectable p65 protein present in either the adjacent or tumor nuclear samples from these patients. The p65 protein was not degraded in these extracts as cytoplasmic p65 was readily detectable by immunoblotting (data not shown). An antibody speci®c for human aactin was used to control for equal loading. This data again diers from data obtained with breast tumor cell lines which show a signi®cant increase in p65 protein in Western analysis (see below).
Both p50 and p52 proteins appear to be normally transcriptionally inactive, except when found in a complex with the IkB homolog Bcl-3 (Bours et al., 1993; Fujita et al., 1993) . Therefore, we probed the breast cancer nuclear extracts for Bcl-3. As shown in Figure 4a , Bcl-3 was found to be signi®cantly elevated in the nuclear extracts of each of the tumor samples analysed as compared to the normal adjacent tissue. These results provide a potential mechanism to explain transcriptional activity associated with nuclear levels of p50 and p52 (see below and see Discussion). In Figure 3 Immunohistochemistry analysis of breast tumor tissue for NF-kB. Sections of paran-embedded tumor (T) and normal adjacent tissue (A) from patient 1 were probed with p65, p50, p52 or c-Rel speci®c antibodies, and bound antibodies were visualized using immunoperoxidase detection. Following antibody speci®c staining, sections were counterstained with hematoxylin contrast with the breast tumors, nuclear extracts derived from breast cancer cell lines exhibit elevated nuclear levels of p65 and p50, but variable expression of p52 and c-Rel (Figure 4b ). As described above, there is a slower mobility of the p65 found in T47D ( Figure  4b ) that is apparent on longer gel migration. Additionally, breast cancer cell lines exhibited virtually no nuclear Bcl-3 (Figure 4b ) which was due to low levels of Bcl-3 mRNA expression (data not shown).
Activation of NF-kB regulated genes in tumorigenic tissue samples
Many of the NF-kB and IkB genes are known to be regulated by NF-kB, thus allowing for the assay of potentially increased kB-dependent gene expression in breast cancer. Thus, the p50 and p52 genes, but not the gene encoding p65, are known to be regulated by NFkB (see Liptay et al., 1994) . In order to determine whether the increase in p50 and p52 levels observed in breast cancer tumor tissue was due to an increase in mRNA, additional tumor samples were obtained and RNA analysis was performed. Enzymatic ampli®cation by PCR is well suited for RNA analyses in this study because the limited sample amount that we were able to obtain was insucient for more standard methods of analysis. Using the reverse transcriptase-polymerase chain reaction (RT ± PCR) under limiting conditions, we generated ampli®ed products which were electrophoresed on agarose gels. Ampli®ed DNA levels were quanti®ed by Southern analysis. As shown in Figure 5 , an increase in mRNA from the p50 and p52 genes is observed in tumor tissue when compared to mRNA levels for these genes in adjacent tissue. Additionally, a dramatic increase in mRNA from the IkBa gene, which is known to be regulated by NF-kB Ghosh et al., 1998) , was observed in tumor samples. Presumably, the Increased mRNA levels of p52, p50, IkB, Bcl-3 and cyclin D1 but not p65 are seen in breast tumors. Total RNA (4 mg) was isolated from tumor and normal adjacent tissue of patients 1 and 7. RT ± PCRs were performed to generate partial cDNA transcripts encoding the NF-kB family members p65, p50 and p52 as well for Bcl-3, cyclin D1, IkBa and a-actin. RT ± PCR products were resolved on agarose gels and detected via Southern blotting using independently derived cDNA probes. Products were ampli®ed 25 cycles with the exception of p65 which required an additional ten cycles for visualization. Exposure times for Southern blots ranged from 24 ± 48 h. In all cases, RT ± PCR products were of the size predicted by their nucleotide sequences NF-kB forms activated in breast cancer can activate expression of the IkBa gene. Interestingly, upregulation of IkBa presumably would not aect the nuclear accumulation of p50 and p52 complexes. When oligos speci®c for p65 were used, an additional ten PCR cycles were necessary in order to visualize any product by Southern analysis. Consistent with our previous ®ndings, there was no increase in p65 mRNA between adjacent and tumor tissue. Additionally, mRNA levels for Bcl-3, which contains NF-kB binding sites in its promoter region (see Ohno et al., 1990) , and for cyclin D1 are elevated in breast tumor tissue as compared to adjacent tissue. Cyclin D1 was recently shown to be transcriptionally regulated by NF-kB (Hinz et al., 1999; Guttridge et al., 1999) . The normalization using human a-actin shows equal PCR products for each sample. This data suggests that the increase in protein seen in Western analysis for p50, p52 and Bcl-3 is caused by an increase in mRNA level due to either the stabilization of the mRNA or, more likely, to an increase in transcription of the NF-kB regulated genes likely through the activation of functional NF-kB activity. The potential regulation of cyclin D1 gene expression in human breast cancer by NF-kB/Bcl-3 complexes is important since cyclic D1 protein expression is unregulated in the great majority of breast tumors. Preliminary data indicate that cyclin D1 can be transcriptionally activated by p50 plus Bcl-3 (S Westerheide and AS Baldwin Jr, in preparation).
Discussion
The results we obtained through EMSA and Western analysis of nuclear extracts isolated from patients with breast cancer along with immunohistochemical studies revealed a distinct pattern of activation of NF-kB subunits as compared to normal, adjacent tissue. Additionally, a dierent pattern of NF-kB expression was found from that seen in commonly used breast cancer cell lines and from that seen following treatment of cells with cytokines or other NF-kB inducers. Thus, breast cancer cell lines exhibit a constitutive level of NFkB activation that consists primarily of the p50/p65 heterodimer and of the p50 homodimer. Consistent with these ®ndings, we have made the observation that longterm culture of a variety of cell lines leads to increased levels of nuclear NF-kB consisting of the p65 subunit (data not shown). However, our data indicate that NFkB binding complexes containing p50, p52 and c-Rel are activated (i.e., nuclear) in human breast cancers without a corresponding consistent activation of the p65 subunit. Similar to our studies, Sovak et al. (1997) found that two of ®ve breast tumor samples exhibited signi®cant p65 nuclear expression. With respect to NF-kB and its potential biological role in breast cancer, our results demonstrate that established breast cancer cell lines may not serve as a completely reliable model for this disease.
Increases in p50, p52 and c-Rel levels and binding activities are detected in breast tumors as compared to non-tumorigenic adjacent tissue. Interestingly, immunohistochemical approaches show a dramatic quantitative increase of p52 in the ductal regions of the breast cancer and not in the invading stromal ®broblasts (Figure 3 ). Previously, it was shown that cellular levels of the 100 kD precursor of p52 were elevated in a majority of breast cancer samples (Dejardin et al., 1995) . However, corresponding nuclear levels of p52 were not analysed in these primary samples. Although c-Rel is known to harbor transcriptional activation domains, both the p50 and p52 subunits have not been shown to be transcriptionally active unless complexed with the IkB homolog Bcl-3 (Bours et al., 1993; Fujita et al., 1993; Schmid et al., 1994) . Consistent with this concept, the phenotype of the Bcl-3 knockout overlaps signi®cantly with that of the p50 and the p52 knockouts (Caamano et al., 1998; Franzozo et al., 1997 Franzozo et al., , 1998 Schwarz et al., 1997) . Importantly, we ®nd that Bcl-3 nuclear levels are increased in breast cancer tissue as compared to the adjacent levels, which is interesting since it was published recently that Bcl-3 can function to increase nuclear levels of p50 (Zhang et al., 1994; Watanabe et al., 1997) . Thus, an increase in nuclear Bcl-3 may function with increased levels of p50 and p52 to account for the enhancement in NF-kB dependent gene expression observed in human breast cancer ( Figure 5 ). Since p50 and p52 are not thought to be directly regulated through complexes with IkBa or IkBb, our data suggest that a pathway is active in breast cancer that functions to increase levels of certain forms of NF-kB that is independent of the normal inductive pathways that involves degradation of one of the IkB subunits. However, we cannot rule out that the increase in nuclear levels of c-Rel found in breast cancer is controlled through a pathway that involves release from a form of IkB. Our data also indicate that levels of mRNAs for p50 and p52 are increased in breast cancer, likely through the transcriptional activation of these genes by active NF-kB complexes Ghosh et al., 1998; Liptay et al., 1994) . This is likely to contribute to the increase in these NFkB subunits in breast cancer. Additionally, increased mRNA levels for Bcl-3 were observed in breast tumors. However, Bcl-3 levels were barely detectable in nuclear or cytoplasmic extracts of breast cancer cell lines and Bcl-3 mRNA levels were relatively low.
Of the NF-kB subunits found activated in human breast cancer, c-Rel and p52 each have been implicated with oncogenesis Gilmore, 1997; Chang et al., 1995) . The p100/p52 gene is found translocated and rearranged in certain lymphomas such that it is overexpressed without the normal ankyrin repeats. Removal of the C-terminal ankyrin repeats of p100/p52 leads to gastric hyperplasia and to enhanced proliferative responses of lymphocytes (Ishikawa et al., 1997) . c-Rel can be transforming when mutated and expressed in retroviral form (Gilmore, 1997) and IkBa expression can delay tumor formation in v-Rel expressing mice . Importantly, we ®nd that Bcl-3 nuclear levels are increased in human breast cancer and Bcl-3 has also been found translocated [t(14;19) ] and overexpressed in certain B-cell lymphomas (McKeithan et al., 1997; Michaux et al., 1997) . Consistent with a role for Bcl-3 in human leukemia, it was found that Bcl-3 transgenic mice exhibit lymphadenopthy and splenomegaly (Ong et al., 1998) .
What is the possible role for elevated NF-kB functional activity in human breast cancer? Our recent data indicated that NF-kB activation suppresses a transformation-associated apoptosis (Mayo et al., 1997) . Thus, NF-kB may serve to suppress a similar apoptosis in developing breast cancer. Consistent with this, Sonenshein and colleagues (Sovak et al., 1997) found that inhibition of NF-kB in a breast cancer cell line led to enhanced cell death. Future experiments will determine if the forms of NF-kB that are activated in human breast tumors provide a cell survival function in the tumor tissue and can activate genes known to suppress apoptosis. This process may also contribute to chemoresistance of breast tumors. Additionally, our recent data and that of others indicates that NF-kB can promote cell cycle progression through the activation of cyclin D1 promoter activity (Hinz et al., 1999; Guttridge et al., 1999) and, thus the activation of NF-kB functional activity may promote the enhanced cell proliferation and overexpression of certain cyclins that are characteristic of breast cancer (Sherr, 1996) .
Materials and methods
Cell culture
All cell lines were obtained from the Lineberger Comprehensive Cancer Center Tissue Culture Core Facility at the University of North Carolina, Chapel Hill. MCF-7 cells were maintained in DMEM, T47D cells were grown in RPMI 1640 medium containing 16 ITS (insulin-transferrin-sodium selenite; Boehringer Mannheim), BT474 cells were cultured in EMEM with ITS, MDA231 cells were grown in Iscoves medium, and SKBR-3 cells were grown in Macoys5A medium. Growth media contained antibiotics and 10% fetal calf serum obtained from Life Technologies.
Tissue samples
Lumpectomy and mastectomy samples from breast cancer patients were separated into tumor tissue and normal adjacent tissue by a pathologist. Samples were either quickly snap frozen in liquid nitrogen, or directly embedded in paran. A total of 17 samples were obtained, of which seven were matched sets of both tumor and normal breast tissue as determined by histological analysis.
Cell extracts and Western blotting
Nuclear extracts from each cell line were prepared as previously described (Finco et al., 1997) . Nuclear extracts from snap frozen tissue sections were prepared by resuspending crushed, frozen samples in sucrose buer (0.3 M sucrose, 60 mM KCl, 15 mM NaCl, 15 mM HEPES pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 14 mM b-mercaptoethanol and 0.1% NP40) followed by dounce homogenization. Nuclei were isolated following double sucrose pelleting through 0.88 M and 1 M sucrose solutions. For Western blotting analysis, equal amounts of protein were separated on an 8% SDSpolyacrylamide gel and transferred to nitrocellulose. Blots were blocked in 5% milk in 16 TBST (Tris Buered Saline, 0.5% Tween 20) and probed with either anti-p50, anti-Bcl-3, anti-a-actin (Santa Cruz Biotechnology), anti-p65 (Rockland), or anti-p52 (Rockland) each at 1 : 1000 dilution in 16 TBST. Blots were probed with a secondary antibody conjugated to horseradish peroxidase (Promega Corp.) at 1 : 10 000 dilution in 16 TBST. Protein bands were visualized with an enhanced chemiluminescence detection system (Amersham Life Science).
Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as described previously (Mayo et al., 1997 ). An oligonucleotide corresponding to an NF-kB site in the H-2K b gene (5'-CAGGGCTGGGGATTCCCATCTCC-CACAGTTTCACTTC-3') was radiolabeled using a-32 PdCTP and the Klenow fragment of DNA polymerase I (Boehringer Mannheim). For antibody supershift analysis, nuclear extracts were preincubated 15 min at room temperature with 1 mg antiserum before the addition of the radiolabeled gel shift probe. Antibodies used in supershift analysis are identical to those utilized for Western blotting described above.
Immunohistochemistry
Formalin-®xed, paran-embedded tissues were cut to 4 mm, and sections were deparanized in xylene, rehydrated, and probed using speci®c NF-kB/Rel antibodies (listed above for Western blotting). Staining was performed using the Vectastain ABC immunoperoxidase staining kit in conjugation with 3',3'-diaminobenzidine (Vector Labs). Tissues were counterstained with Mayer's hematoxylin (Sigma), overlaid with permount mounting solution (Fisher Scienti®c) and placed under coverslips.
RT ± PCR
Snap frozen tissue sections were homogenized in 4 M guanidinium isothiocyanate using a Brinkman Polytron (Westbury). RNA was then isolated by centrifugation through 5.7 M cesium chloride. To produce cDNA, total RNA (4 mg) and random hexamers (200 ng; Life Technologies were dentured at 808C for 10 min and incubated for 60 min at 378C in ®rst strand synthesis buer containing 10 mM DTT (Life Technologies), with 625 mM dNTP (Boehringer Mannheim), and 400 units of MMLV reverse transcriptase (Life Technologies). Resulting cDNAs were diluted 1 : 5 in dH 2 0 and an aliquot was combined with a mixture containing 200 nM of speci®c oligonucleotides, 250 mm dNTP, 1.5 mM magnesium chloride, 16 PCR buer, and 2.5 units of Taq polymerase (Life Technologies). Cycle conditions were the following: denaturation, 948C for 30 s; annealing, 588C for 30 s; and extension, 728C for 1 min. The amount of input cDNA was adjusted ®rst to obtain equal amounts of a-Actin product. Ampli®ed products ranged from 450 ± 550 bp in length. Forward (1) and reverse (2) primers used for RT ± PCR were the following: p65-1, 5'-CGTGGAGGTGTATGATGATGACGTA-3'; p65-2, 5'-CT-AGAATCTAGCTGGAGGGAGGCCA-3', p50-1, 5'-TGG-ATCCTTCTTTGACTCATACAAT-3'; P50-2, 5'-GTCTGC-TGCAGAGCTGCTTGGCGGA-3'; IkBa-1, 5'-GGGACCC-TCAGCAGAGAGGAGGACC-3'; IkBa-2, 5'-GCTTTCA-GTTGTTGTGATGCTGAGA-3'; cyclinD1-1, 5'-ACCCGG-CCTGCTTCCACC; cyclinD1-1, 5'-GCTGCCTCCTGGAG-CTGG. All products were ampli®ed for 25 cycles with the exception of p65 which required a total of 35 cycles for visualization. Ampli®ed products were fractionated on 1.5% agarose gels in 16TBE (Tris Borate-EDTA), visualized by ethidium bromide, transferred to Nytran Plus (Schleicher & Schuell) and hybridized with speci®c NF-kB/Rel probes, radiolabeled with [a-32P]dCTP (Pharmacia BioTech). Hybridizations were performed for 1 h at 688C in QuickHyb Hybridization Solution (Stratagene) as recommended by the manufacturer. Blots were washed once in 26SSC for 15 min at room temperature followed by two washes in 0.16SSC for 30 min at 658C. Exposure times ranged from 1 ± 2 days.
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